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Abstract Background: Tribendimidine is a new anthelmintic agent synthesized by
Chinese scientists. It is a broad spectrum agent with high activity against
parasites. However, its disposition and metabolism remain unknown.
Objective: To investigate the metabolism, disposition, and metabolites of
tribendimidine in healthy human volunteers.
Methods: Twelve healthy Chinese volunteers were chosen after clinical assess-
ment of health status and laboratory tests. They received single oral doses of
tribendimidine 400mg enteric-coated tablets. Blood and urine samples were
collected at scheduled timepoints. Samples were qualitatively and quantita-
tively analyzed by liquid chromatography-mass spectrometric (LC-MS) and
high performance liquid chromatography (HPLC) methods, respectively.
Results: Tribendimidine was rapidly and completely broken down to
p-(1-dimethylamino ethylimino) aniline (dADT) and terephthalaldehyde
(TPAL). Furthermore, dADT was partially transformed to acetylated dADT,
and TPAL completely transformed to terephalic acid (TPAC). The main
pharmacokinetic parameters (– SD) of dADT were as follows: elimination
half life (t½) 4.74– 1.80 h; elimination rate constant (Ke) 0.16– 0.06 h-1; ap-
parent volume of distribution (Vd/F) 12.23 – 8.69L kg-1; apparent total
clearance of the drug from plasma (CL/F) 1.63 – 0.58L h-1 kg-1; area un-
der the plasma concentration-time curve (AUC) from time 0 to time 24 hours
(AUC24) 4.29– 1.88mg mL-1 h; AUC from time zero to infinity (AUC¥)
4.45– 1.81mg mL-1 h; maximum plasma drug concentration (Cmax)
0.64– 0.27mg mL-1; and time to Cmax (tmax) 4.20 – 0.71 h. A total of 35.28%
dADT and 28.50% TPAC were excreted through the urine within 24 hours
after tribendimidine administration.
Conclusion: These results reveal the disposition, metabolism, and main
metabolites of tribendimidine in healthy Chinese volunteers.
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idyne amine, is a new and effective anthelmintic agent,
with broad spectrum activity against helminthes.
It is highly active against Ascaris lumbricoides and
Necator americanus without mutagenic and clas-
togenic effects compared with other anthelmintic
agents.[1] Worldwide, more than 1221million peo-
ple are infected with Ascaris lumbricoides (the
most common intestinal nematode), 795million
people with Trichuris triciura, and 740million
people with hookworms.[2] Tribendimidine is
promising because of its safety profile, broad
spectrum, and high levels of activity.
In clinical and pharmacodynamic studies, Yueyi
et al.[3] and Kuiyang et al.[4] showed that tri-
bendimidine was highly active against hookworm
and Ascaris. The adverse effects of tribendimi-
dine were very mild and transient. Zhongxing and
Yixin[5] compared the therapeutic and adverse
effects of single or combination doses of tri-
bendimidine and ivermectin against human
nematodiasis. It was indicated that tribendimi-
dine combined with ivermectin had the highest
cure rate, suggesting the existence of synergism.
Shuhua et al.[6] assessed the efficacy of artemether,
artesunate, praziquantel, and tribendimidine
against different stages of Clonorchis sinensis
in vivo, and found that the artemisinins and tri-
bendimidine possess important clonorchicidal
properties.
Few studies have focused on the metabolism
and pharmacokinetic profiles of tribendimidine
in humans. In vitro, tribendimidine is unstable and
quickly broken down to p-(1-dimethylamino ethyl-
imino) aniline (dADT) and terephthalaldehyde
(TPAL) in acidic buffer, human blank plasma,
and urine.[7] dADT was demonstrated to be
present in human plasma and urine after oral
administration of tribendimidine enteric-coated
tablets; however, only 40% of the original dose
was recovered, indicating that other metabolites
may be produced. TPAL was not detected in
human plasma, urine, or feces, but its metabolite,
terephalic acid (TPAC), was present in human
urine. dADT and TPAC were detected in human
plasma and urine using liquid chromatography-
mass spectrometric (LC-MS) and high perform-
ance liquid chromatography (HPLC) methods.[7,8]
The disposition of tribendimidine in vivo can be
identified by these same methods. In the present
study, we aimed to identify the distribution, meta-
bolism, and metabolites of tribendimidine in hu-
mans using qualitative and quantitative analyses.
Materials and Methods
Chemicals and Reagents
Tribendimidine, dADT standard (>99%) and
tribendimidine enteric-coated tablets (200mg,
No. 0505226) were provided by Xinhua Pharma-
ceutical Co. Ltd. (Zibo, China). TPAL and TPAC
were purchased from Sinopharm Chemical Re-
agent Co. Ltd. (Shanghai, China). Mirtazapine
standard (>99%) was provided by Kexinwei Phar-
macy Research Company (Jinan, China). Ferulaic
acid was provided by the Chinese National In-
stitute for the Control of Pharmaceutical and
Biological Products (Beijing, China). HPLC-grade
acetonitrile and methanol were purchased from
J.T.Baker (Phillipsburg, NJ, USA). Glacial acetic
acid and triethylamine were purchased from Te-
dia Company (Fairfield, CT, USA).
Instruments
The LC-MS system equipped with electrospray
ionization (ESI) source, HPLC pump, and auto-
sampler (Agilent, Santa Clara, CA, USA) was
used for metabolism analysis and dADT de-
tection in human plasma samples. The Agilent
HPLC andWaters HPLC systems (Milford, MA,
USA) were used to determine dADT and TPAC
levels in human urine samples.
Chromatography and Mass Spectra
Conditions
The LC-MS method was used to examine
dADT levels in human plasma and feces. The
separation was performed using a Hypersil C18
column (250 · 4.6mm inner diameter [ID], 5 mm)
with mobile phase containing ammonium acetate
10mmol/L (containing 0.1% triethylamine) :
acetonitrile (20 : 80, v/v) at 25C. Flow rate was
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1.0mLmin-1. The ESI source was set to positive
ion mode with capillary voltage 4000V, desolva-
tion gas (nitrogen) heated at 350C (11.0Lmin-1),
nebulizer pressure 50 psi, and fragment voltage
90V. Quantification was performed with selected
ion monitoring (SIM) of mass-to-charge ratio
(m/z) 178.1 for dADT.
dADT and TPAC in human urine were ex-
amined using the HPLC method. dADT was
separated through an Extend C18 column (250 ·
4.6mm ID, 5 mm) by isocratic elution using
methanol : acetonitrile : water : triethylamine (35 :
35 : 30 : 0.2, v/v/v/v) at 0.7mL min-1. Mirtazapine
was used as the internal standard and UV detec-
tion was at 249 nm. TPACwas separated through
an Ultimate XB C18 column (200 · 4.6mm ID,
5 mm) by isocratic elution with methanol : 1%
glacial acetic acid (35 : 65, v/v) at 0.8mL min-1.
Ferulaic acid was used as the internal standard
and UV detection was at 240 nm.
The LC-MS method was used to analyze the
metabolite of tribendimidine in urine with an
Agilent Extend C18 column (250mm · 4.6mm
ID, 5 mm) at 25C. Isocratic elution of the analyte
was performed with mobile phase (acetonitrile :
methanol : water : triethylamine [35 : 35 : 30 : 0.2,
v/v/v/v]) at 1.0mL min-1. The analyte was de-
tected and analyzed with ESI ion source in both
positive ion mode and full scan mode. The mo-
lecular weight ranged from 110 to 600. The de-
tection conditions of capillary voltage, source
temperature, drying gas flow, and nebulizer
pressure were 4000V, 350C, 11.0 L min-1, and
50 psi, respectively.
Method Validation and Sample Preparation
dADT (1.0mg mL-1) stock solution was pre-
pared and diluted in ethanol for the working
solutions. Linearity was assessed ranging from
0.5 to 1000 ng mL-1 in plasma and from 5 to
500 mg mL-1 in urine. Similarly, TPAC stock
solution (2.0mg mL-1) was prepared and diluted
in 1% sodium hydroxide for the working sol-
utions. Linearity was assessed ranging from 1 to
400 mg mL-1 in urine.
A calibration curve was constructed on the
basis of peak area and this was analyzed using
weighted linear regression. The lower limit of
quantification (LLOQ) was defined as the lowest
concentration to be produced at least five times
with acceptable precision (relative standard de-
viation [RSD] <20%) and accuracy (80–120% of
nominal concentration). Intra- and inter-day
precision and accuracy were determined by ana-
lyzing spiked samples with low, medium, or high
concentrations for 3 days, and five replicates were
applied. Three aliquots of the spiked samples at
low, medium, or high concentration were stored
for the stability studies of dADT and TPAC.
A total of 0.5mL of plasma, 50 mL of sodium
hydroxide (5mol/L) and 0.3mL of acetonitrile
were added to a 1.5mL polypropylene centrifuge
tube; this was vortex-mixed for 1 minute, and
then centrifuged at 11 132 g (revolutions per mi-
nute) for 5 minutes. The supernatant was trans-
ferred into another 1.5mL polypropylene centrifuge
tube that contained 50–60mg sodium chloride;
this was vortex-mixed for 30 seconds, incubated
for 10 minutes at room temperature, and then
centrifuged for 5 minutes at 11 132 g. A total of
5 mL of the final supernatant was injected for
analysis. Urine samples were diluted and then
analyzed without disposition after adding the
internal standard (mirtazapine for dADT and
ferulaic acid for TPAC).
Study Design
Twelve healthy Chinese volunteers (six men
and six women, aged 23–27 years) were screened
after clinical assessment of health status and
laboratory tests. Informed consents were signed
before starting the experiments. The protocol was
approved by the Ethic Committee of Qilu Hos-
pital, and was conducted in accordance with the
Declaration of Helsinki.
The volunteers fasted for 10 hours. After oral
administration of tribendimidine enteric-coated
tablets (400mg), 4mL of blood was collected
before (0 hours), and 0.5, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5,
6, 8, 12, and 24 hours after administration, and a
liquor of urine samples were collected at time
zero (blank sample), 0–2, 2–4, 4–6, 6–8, 8–12, and
12–24 hours after administration. Plasma was
separated, collected, and stored at -20C for
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Fig. 1. The typical chromatograms of (a) blank plasma (1), plasma sample spiked with p-(1-dimethylamino ethylimino) aniline [dADT] (2), and
plasma sample from a volunteer 1 hour after oral administration of tribendimidine (3); (b) blank urine (1), urine sample spiked with dADT and
mirtazapine [internal standard; IS] (2), and urine sample from a volunteer 4 hours after oral administration of tribendimidine spiked with IS (3);
and (c) blank urine (1), urine sample spiked with terephalic acid (TPAC) and ferulaic acid [IS] (2), and urine sample from a volunteer 4 hours
after oral administration of tribendimidine spiked with IS (3). AU= absorb unit; mAU =mini-absorb unit.
86 Yuan et al.
ª 2010 Yuan et al., publisher and licensee Adis Data Information BV. Drugs R D 2010; 10 (2)
analysis. The Drug and Statistic (DAS, version
2.0)[9] program was used to fit the compartmental
model of dADT and calculate the main pharm-
acokinetic parameters as follows: elimination
half-life (t½), elimination rate constant (Ke), area
under the plasma concentration-time curve from
time 0 to 24 hours (AUC24), area under the plas-
ma concentration-time curve from time zero to
infinity (AUC¥), apparent total clearance of the
drug from plasma (CL/F), and apparent volume
of distribution (Vd/F). The maximum plasma
drug concentration (Cmax) and the time to reach
Cmax (tmax) were also observed. Accumulated
excretion rates of dADT and TPAC in urine were
obtained by the following equation: accumulated
excretion rate = accumulated excretion amount/
time · 100%.
Chromatograms of blank urine samples were
comparedwith those of urine samples collected after
oral administration of tribendimidine enteric-coated
tablets. The natures of the metabolites were de-
termined by their standard and molecular weight.
Results
Validation of Analytical Methods
The typical chromatograms of plasma and di-
luted urine are shown in figure 1. No interfer-
ences were found in analyzed plasma and urine
samples. The retention time of dADT in plasma
was approximately 6.08 minutes. The retention
times of dADT and its internal standard in urine










































Fig. 2. (a) The plasma concentration vs time profile of p-(1-dimethylamino ethylimino) aniline (dADT) [n =12] and (b) the urine excretion rate
vs time curves of dADT and terephalic acid (TPAC) [n =6] after oral administration of tribendimidine 400mg enteric-coated tablets.
Table I. Precision (relative standard deviation [RSD]) and accuracy for the determination of p-(1-dimethylamino ethylimino) aniline (dADT)
and terephalic acid (TPAC) in human plasma and urine
Variable Concentration RSD (%) Accuracy (% of nominal
concentration)intra-day inter-day
dADT
Plasma 1 ng mL-1 2.93 4.88 97.72
50 ng mL-1 1.22 1.74 96.78
800 ng mL-1 1.86 3.22 97.12
Urine 10 mg mL-1 2.98 2.66 99.82
50 mg mL-1 0.59 2.52 99.26
400 mg mL-1 1.37 2.79 97.03
TPAC
Urine 3 mg mL-1 5.37 6.24 105.99
25 mg mL-1 4.04 5.62 107.40
200 mg mL-1 3.58 3.89 108.49
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retention times of TPAC and its internal standard
in urine were 9.86 and 12.06 minutes, respectively.
The calibration curves of dADT were linear
above the concentration ranges in plasma (n = 5)
and urine (n = 5) with the regression equations
(weight = 1/X2), which were Y = 14767.7001X+
783.85047 for plasma and Y = 4.283X + 0.001 for
urine, and the correlation coefficients were 0.999.
The LLOQ of dADT was 0.5 ng mL-1 in plasma
(n = 5) and 5 mg mL-1 in urine (n = 5).
The calibration curve of TPAC was linear
above the concentration range in urine. The re-
gression equation was Y= 0.0268X – 0.00147 with
a correlation coefficient of 0.9954. The LLOQ of
TPAC was 1 mg mL-1 in urine (n = 5).
The intra- and inter-assay precision and accu-
racy of dADT and TPAC were acceptable for the
analysis. All data were obtained from five repli-


































Fig. 3. Chromatograms of (a) blank urine and (b) urine collected 4 hours after administration of tribendimidine. Peaks 1 and 2 in (b) corre-




















































Fig. 4. Mass spectrum of (a) acetylated p-(1-dimethylamino ethylimino) aniline (dADT) and (b) dADT. m/z =mass-to-charge ratio.
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The stability of dADT in human plasma and
urine, and TPAC in human urine were inves-
tigated under different storage and process con-
ditions. The analyte was assayed with three con-
centrations. dADT was stable after being frozen
for 7 days at -20C (90.00–94.70% of the initial
value in plasma and 97.84–99.88% in urine), and
stable after two freeze-thaw cycles (-20C/room
temperature) [92.35–100.68% of the initial value
in plasma and 98.64–99.78% in urine]. TPAC was
stable after being frozen for 7 days at -20C
(95.32–99.70% of the initial value) or two freeze-
thaw cycles (-20C/room temperature) [96.75–
102.13% of the initial value].
Metabolism and Disposition of Tribendimidine
and Its Metabolites
The plasma concentration and urine excretion
rate versus time curves of dADT and TPAC in hu-
man plasma and urine are shown in figure 2. The
kinetics of dADT fit a one-compartmental mod-
el. The main pharmacokinetic parameters were
as follows: t½ 4.74– 1.80h;Ke 0.16– 0.06h-1; Vd/F
12.23– 8.69L kg-1; CL/F 1.63– 0.58L h-1 kg-1;
AUC24 4.29 – 1.88 mg mL-1  h; AUC¥ 4.45 –
1.81 mg mL-1  h; Cmax 0.64 – 0.27 mg mL-1;
and tmax 4.20 – 0.71 h. Accumulated excretion
rates of dADT and TPAC were 35.28 – 13.00%
and 28.50 – 11.92% in urine, respectively.
The chromatograms of blank urine samples
and urine samples collected after oral adminis-
tration of tribendimidine are shown in figure 3.
Two peaks of retention time, 3.2 minutes and 4.1
minutes, were validated by LC-MS. Peak 1 (pro-
tonated molecular ion [M + H]+, 220.2) and peak
2 ([M + H]+, 178.2) are shown in figures 4a and
4b, respectively. Peak 2 is dADT and peak 1 is the
acetylated metabolite of dADT based on their
molecular weight and standard.
Discussion
In this study, the LC-MS and HPLC methods
for determination of dADT and TPAC in human
plasma and urine were established. The high
sensitivity for dADT was obtained using the
electrospray ion source and positive selective ion
monitoring mode. The mobile phase for the LC-
MS method was optimized by comparing various




















Low pH or enzyme
+
dADT (35.28% excreted through urine)
Partly metabolized
Acetylated dADT TPAC (28.50% excreted through urine)
Completely metabolized
TPAL (undetected in urine)
Fig. 5. The breakdown of tribendimidine in the human body. dADT = p-(1-dimethylamino ethylimino) aniline; TPAC = terephalic acid;
TPAL = terephthalaldehyde.
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percentages of methanol : ammonium acetate
10mmol/L or acetonitrile : ammonium acetate
10mmol/L to improve separation and to enhance
sensitivity. Use of acetonitrile and triethylamine,
instead of methanol, allowed appropriate re-
tention time and sharp peak shape, respectively.
No endogenous interferences were found under
the optimized LC-MS conditions.
The results indicated that tribendimidine was
immediately broken down to dADT and TPAL
after oral administration of enteric-coated tab-
lets. dADT in plasma can be used to evaluate
the pharmacokinetic behavior of tribendimidine
in vivo after its oral administration. The metabo-
lite TPAL was also not detected in either urine or
plasma, because it was quickly metabolized to a
more stable metabolite (TPAC), which was found
in urine. dADT was further metabolized to an
acetylated form by acetyltransferase, as shown in
figure 5.
dADT is the major metabolite of tribendimi-
dine. However, so far, there have been no studies
to demonstrate its anti-parasitic activity. The
activity of dADT, degree of acetylation, and ac-
tivity of acetylated dADT are expected to be
identified in future studies.
Conclusion
Specific, sensitive, and rapid methods were
developed to determine dADT and TPAC, and to
investigate the disposition and metabolism of
tribendimidine in human plasma and urine. Our
data suggest that tribendimidine is rapidly broken
down to dADT and TPAL. Furthermore, dADT
was partially transformed to acetylated dADT,
and TPAL was completely transformed to TPAC.
The anti-parasitic activity of dADT and its ace-
tylated metabolite, and the degree of its acetyla-
tion need further investigation.
Acknowledgments
No sources of funding were used to assist in the prepara-
tion of this article. The authors have no conflicts of interest to
declare that are directly relevant to the content of this article.
References
1. Shuhua X, Huiming W, Tanner M, et al. Tribendimidine: a
promising, safe and broad-spectrum anthelmintic agent
from China. Acta Trop 2005; 94: 1-14
2. De Silva NR, Brooker S, Hotez PJ, et al. Soli-transmitted
helminth infections: updating the global picture. Trends
Parasitol 2003; 19: 547-51
3. Yueyi F, Wenjia L, Qiming Z, et al. Study on the efficacy of
tribendimindine for treatment of intestinal nematode in-
fections. Chin J Schisto Control 2002; 14: 125-7
4. Kuiyang Z, Zhongxing W, Yisheng L, et al. Clinical observa-
tions on therapeutic effect of tribendimidine against hook-
worm, Ascaris, Trichuris and Enterobius human infections.
J Fract Parasit Dis 2002; 10: 149-51
5. Zhongxin W, Yixin Q. Therapeutic effect of tribendimidine
combined with ivermectin against human intestinal nem-
atode infection. Parast Infec Dis 2003; 1: 59-61
6. Shuhua X, Jian X, Tanner M, et al. Artemether, artesunate,
praziquantel and tribendimidine administered singly at dif-
ferent dosages against Clonorchis sinensis: a comparative in
vivo study. Acta Tropica 2008; 106: 54-9
7. Guiyan Y, Benjie W, Chunmin W, et al. LC-MS determi-
nation of p-(1-dimethylamino ethylimino) aniline: a metab-
olite of tribendimidine in human plasma. Chromatographia
2008; 68: 139-42
8. Jie X, Guiyan Y, Chunmin W, et al. Determination of uri-
nary tribendimidine metabolite-terephthalic acid by HPLC.
J Shandong Univ Health Sci 2008; 46: 1016-9
9. Zhiyang C, Qingshan Z, Ruiyuan S. Functions of the DAS
software for farmacological calculation. Chin Pharma. Chin
J Clin Pharmacol Ther 2002; 7: 562-4
Correspondence: Dr Ruichen Guo, 107 Wenhua Xi Road,
Jinan Shandong Province, 250012, China.
E-mail: grc7636@126.com
90 Yuan et al.
ª 2010 Yuan et al., publisher and licensee Adis Data Information BV. Drugs R D 2010; 10 (2)
